D.A. Davidson & CO. Buys 1,783 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Posted by Defense World Staff on Jul 11th, 2023

D.A. Davidson & CO. lifted its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 11.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,865 shares of the medical research company’s stock after acquiring an additional 1,783 shares during the quarter. D.A. Davidson & CO.’s holdings in IQVIA were worth $3,326,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of IQV. HighTower Advisors LLC grew its position in shares of IQVIA by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after buying an additional 118 shares during the last quarter. Prudential PLC acquired a new position in shares of IQVIA in the 1st quarter valued at $741,000. Baird Financial Group Inc. boosted its stake in shares of IQVIA by 2.3% during the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in shares of IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 144 shares in the last quarter. Finally, Covestor Ltd grew its holdings in IQVIA by 82.2% in the first quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares during the period. Institutional investors own 86.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IQV. Stifel Nicolaus dropped their target price on shares of IQVIA from $269.00 to $255.00 in a research report on Friday, April 28th. Wells Fargo & Company decreased their target price on IQVIA from $235.00 to $220.00 in a research report on Monday, May 1st. Robert W. Baird reduced their price objective on IQVIA from $240.00 to $235.00 in a research note on Friday, April 28th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, Barclays upped their price target on IQVIA from $230.00 to $250.00 in a research report on Tuesday, June 27th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $254.50.

Insider Transactions at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 5,820 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $201.89, for a total transaction of $1,174,999.80. Following the sale, the insider now directly owns 1,973 shares in the company, valued at approximately $398,328.97. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $219.43 on Tuesday. The firm has a 50-day simple moving average of $204.78 and a two-hundred day simple moving average of $207.75. The company has a debt-to-equity ratio of 1.99, a current ratio of 0.80 and a quick ratio of 0.80. IQVIA Holdings Inc. has a 1-year low of $165.75 and a 1-year high of $249.11. The stock has a market cap of $40.72 billion, a PE ratio of 39.47, a P/E/G ratio of 2.19 and a beta of 1.41.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Thursday, April 27th. The medical research company reported $2.13 EPS for the quarter, missing analysts’ consensus estimates of $2.21 by ($0.08). IQVIA had a return on equity of 30.95% and a net margin of 7.28%. The firm had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.61 billion. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.23 EPS for the current year.

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.